CDK4 and breast carcinoma: Although our data show that targeting PI3K is likely to benefit patients with PIK3CA-mutant ER+/HER2− breast cancer that has progressed on CDK4/6-targeted therapy, targeting mTORC1 may provide another therapeutic option for patients with PIK3CA wild-type breast cancer.